The global immunotherapy drugs market size was valued at USD 290 billion in 2025 and is projected to grow from USD 323.06 billion in 2026 to USD 766.24 billion by 2034, registering a CAGR of 11.4% during the forecast period from 2026 to 2034. North America dominated the immunotherapy drugs market with a market share of 42.6% in 2025.
Immunotherapy drugs are medicines that help the body's immune system recognize and fight diseases such as cancer, autoimmune disorders, and certain infections. These drugs work by boosting, blocking, or modifying immune responses to improve treatment outcomes. Their use is increasing due to the growing number of cancer cases, ongoing advances in biotechnology, and the development of targeted and personalized treatment options.
Download a Free Sample To learn more about this report,
Expansion of Immunotherapy Into Earlier Lines of Cancer Treatment
Immunotherapy drugs are increasingly being incorporated into treatment settings that occur earlier in the cancer-care pathway rather than being reserved primarily for advanced or previously treated disease. This shift is increasing the eligible patient population and allowing immune-based therapies to be used alongside surgery, chemotherapy, or radiation. Earlier intervention is therefore broadening the clinical role of immunotherapy across multiple tumor types.
In June 2025, the U.S. Food and Drug Administration approved pembrolizumab as neoadjuvant and adjuvant treatment for resectable locally advanced head and neck squamous cell carcinoma, marking its first perioperative approval in this disease.
Increasing Development of Alternative Immunotherapy Delivery Methods
Immunotherapy development is increasingly focused not only on new drug targets but also on improving how established therapies are administered. Subcutaneous formulations can potentially shorten administration time and reduce the burden associated with intravenous infusions while maintaining access to established immune-based treatments. This is encouraging drug developers to pursue more convenient delivery formats.
In September 2025, the U.S. Food and Drug Administration approved a subcutaneous formulation of pembrolizumab and berahyaluronidase alfa for the same solid-tumor indications covered by intravenous pembrolizumab.
Increasing Cancer Incidence Expands the Addressable Treatment Population
The growing global burden of cancer is increasing the number of patients requiring systemic therapies, including immune-based treatments. As immunotherapy becomes established across a wider range of malignancies, increases in cancer incidence can translate into a larger potential population eligible for these drugs. Continued expansion of oncology treatment demand therefore supports the underlying market.
In February 2025, the World Health Organization's cancer agency projected that more than 35 million new cancer cases could occur globally in 2050, representing a substantial increase from 2022 levels.
High Treatment Costs Can Limit Access to Immunotherapy
Many immunotherapy drugs involve complex development, manufacturing, administration, and monitoring requirements, which can result in high treatment costs. The financial burden may be particularly restrictive where reimbursement coverage is limited or healthcare budgets are constrained. Cost considerations can therefore affect patient access and the speed at which newer immunotherapies are incorporated into treatment systems.
In January 2025, the American Society of Clinical Oncology continued identifying the financial burden of cancer care as a major concern for patients, including costs associated with increasingly sophisticated cancer treatments.
Expansion of Biomarker-Guided Immunotherapy
Biomarker testing is creating opportunities to identify patients who are more likely to benefit from specific immunotherapy drugs. Molecular and protein-based biomarkers can help select appropriate treatment populations and reduce the use of therapies where the likelihood of response is lower. Greater integration of companion diagnostics with immunotherapy development can therefore support more targeted treatment strategies.
In April 2025, the U.S. Food and Drug Administration approved nivolumab combined with ipilimumab for microsatellite instability-high or mismatch repair-deficient colorectal cancer, reinforcing the role of tumor biomarkers in selecting patients for immunotherapy.
Managing Serious Immune-Mediated Adverse Reactions
Immune-based therapies can activate the immune system strongly enough to cause inflammatory effects in healthy tissues. These immune-related toxicities can affect multiple organs and may require corticosteroids, immunosuppressive treatment, hospitalization, or treatment interruption. Managing these reactions while preserving anticancer activity remains a major clinical challenge.
In October 2025, the U.S. Food and Drug Administration added a boxed warning for immune effector cell-associated enterocolitis following treatment with a CAR T-cell immunotherapy, highlighting the need for continued monitoring and management of serious immune-mediated complications.
Monoclonal Antibodies Segment Dominated the Market with 68.5% Share in 2025
The monoclonal antibodies segment dominated the global immunotherapy drugs market with a 68.5% share in 2025. These therapies are widely used to treat different types of cancer and autoimmune diseases because they target specific cells while causing less damage to healthy tissues. Their proven effectiveness, growing number of approved products, and increasing use in hospitals continue to support the segment's leading position.
The vaccines and immunomodulators segments are also growing steadily. Therapeutic vaccines are gaining attention as researchers develop new ways to strengthen the body's immune response against diseases. At the same time, immunomodulators are being used more often to manage autoimmune disorders and chronic inflammatory conditions by helping regulate the immune system.
Continuous research in immunology, increasing clinical trials, and the development of combination therapies are expected to create new opportunities across all treatment types. As more advanced immunotherapies enter the market, demand for these products is likely to grow further.
Request Customizationto receive a tailored report.
Cancer Segment Dominated the Market with 61.3% Share in 2025
The cancer segment dominated the global immunotherapy drugs market with a 61.3% share in 2025. Immunotherapy has become an important part of cancer treatment, offering new options for patients with lung cancer, melanoma, breast cancer, and several other types of cancer. Growing awareness, earlier diagnosis, and increasing access to advanced treatments continue to drive demand in this segment.
The autoimmune and inflammatory diseases segment is also expanding as more biologic therapies become available for conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. At the same time, the infectious diseases segment is growing as researchers continue to develop immune-based treatments and vaccines to improve disease prevention and patient outcomes.
Ongoing investment in research, expanding approval of new immunotherapy drugs, and better understanding of immune-related diseases are expected to support growth across all indication areas over the forecast period.
Speak to an Analystto discuss market opportunities.
North America immunotherapy drugs market accounted for 42.6% of the global market, reaching USD 123.54 billion in 2025, and is projected to grow at a CAGR of 10.2% during the forecast period. The region leads the market because of strong research activities, high healthcare spending, and early adoption of advanced cancer treatments. Growing approvals of new immunotherapy drugs and increasing investment in biotechnology are also supporting market growth.
The U.S. market was valued at USD 105.01 billion in 2025, making it the largest contributor in North America. Strong pharmaceutical research, rising use of immunotherapy for cancer treatment, and increasing investment in precision medicine continue to drive market growth.
Canada's market reached USD 18.53 billion in 2025. Growing clinical research, better access to advanced therapies, and increasing healthcare spending are helping the market expand steadily.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe immunotherapy drugs market accounted for 27.4% of the global market, reaching USD 79.46 billion in 2025, and is expected to register a CAGR of 9.7% during the forecast period. Rising cancer cases, increasing use of targeted therapies, and strong government support for healthcare innovation continue to drive market growth. The region is also seeing growing investment in clinical trials and biologic drug development.
Germany's market accounted for USD 23.04 billion in 2025. A strong pharmaceutical industry, advanced healthcare facilities, and increasing use of innovative cancer therapies continue to support market growth.
The UK market was valued at USD 15.89 billion in 2025. Growing investment in oncology research, expanding access to immunotherapy treatments, and supportive healthcare policies continue to contribute to market growth.
Asia Pacific immunotherapy drugs market accounted for 21.8% of the global market, valued at USD 63.22 billion in 2025, and is projected to register a CAGR of 12.9% during the forecast period. Rising healthcare spending, increasing cancer awareness, and improving access to advanced treatments are driving market growth across the region. Governments are also investing in biotechnology research and modern healthcare infrastructure.
Japan's market generated USD 11.38 billion in 2025. Strong pharmaceutical innovation, increasing use of biologic drugs, and advanced cancer care continue to support market growth.
China's market accounted for USD 32.87 billion in 2025, representing the largest share within Asia Pacific. A large patient population, expanding biotechnology sector, and rising investment in cancer treatment continue to drive market growth.
Middle East & Africa immunotherapy drugs market accounted for 3.3% of the global market, totaling USD 9.57 billion in 2025, and is anticipated to grow at a CAGR of 9.4% during the forecast period. Improving healthcare infrastructure, increasing cancer diagnosis rates, and rising access to advanced medicines are supporting market growth across the region.
The UAE market was valued at USD 3.45 billion in 2025. Government investment in modern healthcare facilities, growing availability of advanced cancer treatments, and increasing focus on precision medicine continue to support market growth.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Anti-Osteoporosis Therapy and Fracture Healing Market Size, 2034
United Arab Emirates Influenza Treatment Market Size, 2034
North America Multiple Electrolytes Injection Market Size by 2034
North America Tulathromycin Market Size & Trends By 2034
Precision Cardiology Market Size, Share, Growth, Analysis, 2034
Europe Aesthetic Medicine Market Size, Top Share, Forecast ,2034
We are featured on:
sales@straitsresearch.com